Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
5.39
-0.34 (-5.93%)
At close: Oct 23, 2026, 4:00 PM EDT
5.38
-0.01 (-0.19%)
After-hours: Oct 23, 2026, 7:30 PM EDT
Kyverna Therapeutics Employees
Kyverna Therapeutics had 149 employees as of June 30, 2026. The number of employees increased by 20 or 15.50% compared to the same quarter last year. That makes Kyverna Therapeutics the 28,893rd largest employer in the world and 3,671st in the United States.
Employees
149
Change (1Y)
20
Growth (1Y)
15.50%
Revenue / Employee
n/a
Profits / Employee
-$1,024,416
Market Cap
333.34M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 149 | 20 | 15.50% |
| Mar 31, 2026 | 129 | 10 | 8.40% |
| Dec 31, 2025 | 130 | 18 | 16.07% |
| Sep 30, 2025 | 129 | 10 | 8.40% |
| Jun 30, 2025 | 129 | 17 | 15.18% |
| Mar 31, 2025 | 119 | 19 | 19.00% |
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Sep 30, 2024 | 119 | 30 | 33.71% |
| Jun 30, 2024 | 112 | 23 | 25.84% |
| Mar 31, 2024 | 100 | - | - |
| Dec 31, 2023 | 96 | - | - |
| Sep 30, 2023 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Capricor Therapeutics | 231 |
| Enanta Pharmaceuticals | 120 |
| Orchestra BioMed Holdings | 86 |
| Atea Pharmaceuticals | 55 |
| X4 Pharmaceuticals | 45 |
| Zura Bio | 40 |
| Fennec Pharmaceuticals | 35 |
| vTv Therapeutics | 26 |
KYTX News
- 2 days ago - Kyverna Therapeutics highlights updated clinical data with Miv-cel - TheFly
- 2 days ago - Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 - GlobeNewsWire
- 3 days ago - Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 4 days ago - Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto - GlobeNewsWire
- 18 days ago - Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026 - GlobeNewsWire
- 4 weeks ago - Kyverna Therapeutics Transcript: Study update - Transcripts
- 4 weeks ago - Kyverna Therapeutics Press release: Study update - Filings
- 4 weeks ago - Kyverna Therapeutics Slides: Study update - Filings